| abstract |
The present invention relates to a vaccine composition for use in in vivo administration, comprising a pathogen (attenuated) or a commensal modified to constitute a pre-targeting vector, the pre-targeting vector comprising one or more pendent reactive moieties capable of forming a high affinity interaction with a complementary moiety residing on an immunogenic conjugated element. |